NCT01507077View on ClinicalTrials.gov

ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Obesity
Interventions
DRUG

ZGN-440

Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.

DRUG

ZGN-440 sterile diluent

Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.

Trial Locations (1)

Unknown

Q-Pharm Clinics, Royal Brisbane and Women's Hospital, Brisbane

All Listed Sponsors
lead

Zafgen, Inc.

INDUSTRY

NCT01507077 - ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity | Biotech Hunter | Biotech Hunter